Item 7. Management’s Discussion and Analysis
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
References to the “Company,”
“us,” “our,” or “we” refer to A SPAC III Acquisition Corp. The following discussion and analysis of
our financial condition and results of operations should be read in conjunction with our audited financial statements and related notes
herein.
The following discussion and
analysis of the Company’s financial condition and results of operations should be read in conjunction with our audited financial
statements and the notes related thereto which are included in “Item 8. Financial Statements and Supplementary Data” of this
Annual Report on Form 10-K. Certain information contained in the discussion and analysis set forth below includes forward-looking statements.
Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including
those set forth under “Special Note Regarding Forward-Looking Statements,” “Item 1A. Risk Factors” and elsewhere
in this Annual Report on Form 10-K.
19
Overview
We are a blank check company
incorporated in the British Virgin Islands as a business company and incorporated for the purpose of effecting a merger, share exchange,
asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. We intend to effectuate
our initial business combination using cash from the proceeds of our Initial Public Offering and the private placement of the Private
Placement Units, the proceeds of the sale of our securities in connection with our initial business combination.
We expect to continue to incur
significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete a business combination will
be successful.
Recent Developments
On December 31, 2024, the
Company entered into an agreement with HDEducation Group Limited, a Cayman Islands exempted company (“HD Group”) (the “HD
Group Agreement”). HD Group is headquartered in Anji County, China, and is a comprehensive service platform for students pursuing
university education globally. The Agreement is intended to express a mutual indication of interest, and remains subject, in all respect,
to the execution of definitive agreements. Pursuant to the terms of the Agreement, the aggregate consideration to be paid to existing
shareholders of HD Group is $300,000,000, which will be paid entirely in stock, comprised of newly issued Class A ordinary shares and
Class B ordinary shares of A SPAC III Mini Acquisition Corp., a then to-be-formed British Virgin Islands business company and the Company’s
wholly owned subsidiary (the “PubCo”) at a price of $10.00 per share. On May 21, 2025, the HD Group Agreement was terminated
by mutual agreement by the Company and HD Group.
On January 24, 2025, the Company
entered into an agreement with Bioserica International Limited, a British Virgin Islands business company (“Bioserica”) (the
“Bioserica Agreement”). Bioserica is in the business of researching and developing, manufacturing, marketing and sales of
bio-based antimicrobial materials. The Agreement is intended to express a mutual indication of interest, reflects additional terms negotiated,
and remains subject, in all respect, to the execution of definitive agreements.
On May 23, 2025, the Company
entered into a merger agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”)
with (i) Bioserica, (ii) PubCo, and (iii) A SPAC III Mini Sub Acquisition Corp., a British Virgin Islands business company formed as a
wholly owned subsidiary of PubCo on February 3, 2025 (“Merger Sub”).
Pursuant to the Merger Agreement,
among other things, (i) the Company will merge with and into PubCo, the separate corporate existence will cease and PubCo will continue
as the surviving corporation (the “Reincorporation Merger”), and (ii) the Merger Sub will merge with and into Bioserica and
Bioserica will continue as the surviving company under the laws of the British Virgin Islands and become a wholly owned subsidiary of
PubCo (the “Acquisition Merger”). Pursuant to the terms of the Merger Agreement, the aggregate consideration for the Acquisition
Merger is $217,860,000, consisting of (i) $200,000,000, payable in the form of 20,000,000 newly issued PubCo Class B ordinary shares,
valued at $10.00 per share; and (ii) $17,860,000, payable in the form of 1,786,000 newly issued PubCo Class A ordinary shares, valued
at $10.00 per share (assuming that Bioserica would receive an aggregate of $12,500,000 investment from third parties prior to Closing).
The Merger Agreement contains
customary representations, warranties and covenants of the parties thereto. The consummation of the proposed Merger is subject to certain
conditions as further described in the Merger Agreement.
20
The foregoing description
of the Merger Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Merger Agreement,
a copy of which is filed as Exhibit 2.1 to the Current Report on Form 8-K filed on May 27, 2025, and incorporated by reference herein.
Concurrently with the
execution of the Merger Agreement, Bioserica, PubCo, the Company and a shareholder of Bioserica (the “Supporting
Shareholder”) entered into a voting and support agreement (“Voting and Support Agreement”) pursuant to which such
the Supporting Shareholder has agreed, among other things, to vote in favor of the Acquisition Merger, the adoption of the Merger
Agreement and any other matters necessary or reasonably requested by Bioserica, PubCo or the Company for consummation of the
Acquisition Merger and the other transactions contemplated by the Merger Agreement. In addition, the Supporting Shareholder has
agreed not to sell, assign, encumber, pledge, hypothecate, dispose, loan or otherwise transfer the shares of the Company owned of
record and beneficially by such Supporting Shareholder or over which such Supporting Shareholder has voting power, prior to the
earlier to occur of (a) the closing of the Acquisition Merger, (b) the termination of the Merger Agreement, and (c) written
agreement of the Supporting Shareholder, on the one hand, and the Company and PubCo, on the other hand.
On September 10, 2025, the
Company completed an internal reorganization, pursuant to which Merger Sub became a wholly owned subsidiary of the Company (the “Reorganization”).
As part of the Reorganization, PubCo transferred 100% of the issued and outstanding equity of Merger Sub to the Company.
On October 27, 2025, the Company
convened its extraordinary general meeting (the “2025 EGM”) at which the shareholders voted pursuant to the definitive proxy
statement, filed by the Company with the Securities and Exchange Commission on October 10, 2025 and mailed by the Company to its shareholders
on or about October 10, 2025.
As of October 6, 2025, the
record date for the 2025 EGM, there were 8,055,000 ordinary shares outstanding and entitled to vote. At the 2025 EGM, there were 7,113,684
ordinary shares voted by proxy or in person, representing 88.31% of the total ordinary shares as of the record date, and constituting
a quorum for the transaction of business. The shareholders approved the Extension Amendment Proposal, and the Company filed the amended
and restated memorandum and articles of Association (the “Amended Charter”) with the Registrar of Corporate Affairs at the
British Virgin Islands. Pursuant to the Amended Charter which is effective on October 27, 2025, the Company has up to 24 months from its
initial public offering (i.e., until November 12, 2026) to consummate an initial business combination. The Amended Charter was filed as
an exhibit to the Current Report on Form 8-K, filed on October 27, 2025.
In connection with the shareholders’
vote at the 2025 EGM, 5,717,419 additional Class A ordinary shares were redeemed for $59,502,058. Immediately after the redemption, there
was approximately $2.9 million remaining in the Trust Account and Sponsor holds approximately 76.4% of the Company’s 2,337,581 outstanding
ordinary shares.
On October 25, 2025, the Sponsor
entered into an assignment of economic interest agreement (the “Assignment of Economic Interest Agreement”) with an unaffiliated
third party. In exchange for such third party agreeing to vote 621,084 shares of the Company’s Class A ordinary shares sold in its
initial public offering in favor of the proposal to amend and restate the Company’s amended and restated memorandum and articles
of association to allow the Company to extend the date by which it has to consummate a business combination for an additional twelve (12)
months from November 12, 2025 to November 12, 2026 (the “Charter Amendment Proposal”), the Sponsor agreed to transfer to such
third party or third parties an aggregate of 100,000 shares of the Company’s Class B ordinary shares held by the Sponsor immediately
following the release or expiration of any transfer restrictions after the consummation of an initial business combination.
On January 16, 2026, pursuant
to the Exchange Agreement between the Company and the Sponsor, the Sponsor transferred and delivered to the Company 1,499,900 Class B
ordinary shares in exchange for 1,499,900 Class A ordinary shares (the “Share Exchange”). The 1,499,900 Class A ordinary shares
issued in connection with the Share Exchange are subject to the same restrictions as applied to the Class B ordinary shares before the
Share Exchange, including, among other things, certain transfer restrictions, waiver of redemption rights and the obligation to vote in
favor of an initial business combination as described in the Prospectus.
Results of Operations
We have neither engaged in
any operations nor generated any operating revenues to date. Our only activities from inception through December 31, 2025 were organizational
activities and those necessary to prepare for the IPO, and, following our IPO, searching for a Business Combination target and the negotiation
with potential targets for an initial Business Combination. We do not expect to generate any operating revenues until after the completion
of our initial business combination. We expect to generate non-operating income in the form of interest income on marketable securities
held after the IPO. We expect that we will incur increased expenses as a result of being a public company (for legal, financial reporting,
accounting and auditing compliance), as well as for due diligence expenses in connection with searching for, and completing, a Business
Combination.
21
For the year ended December
31, 2025, we had net income of $1,343,931 which consisted of general and administrative expenses of $827,300, offset by total interest
income from our bank account and investments in Trust Account of $2,171,231
For the year ended December
31, 2024, we had net loss of $226,383, which consisted of general and administrative expenses of $587,106, offset by total interest income
from our bank account and investments in Trust Account of $360,723.
Liquidity and Capital Resources
The Company’s liquidity
needs prior to the closing of IPO were satisfied through a payment from the Sponsor of $25,000 (see Note 5) for the Founder Shares to
cover certain offering costs and the loan under an unsecured promissory note from the Sponsor of up to $350,000 (see Note 5). As previously
disclosed on a Current Report on Form 8-K dated November 8, 2024, on November 12, 2024, on November 12, 2024, the Company consummated
the IPO of 5,500,000 units (the “Units”). Each Unit consists of one Class A Ordinary Share (“Public Share”) and
one right (“Public Right”) to receive one-tenth of one ordinary share upon the consummation of an initial business combination.
The Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $55,000,000. The Company granted the underwriters
a 45-day option to purchase up to 825,000 additional Units to cover over-allotments (the “Over-Allotment Option Units”), if
any. The underwriters notified their partial exercise of the Over-Allotment Option on November 15, 2024, and closed the Over-Allotment
Option on November 19, 2024. The total aggregate issuance by us of 6,000,000 units (which includes the partial exercise of the Over-Allotment
Option) at a price of $10.00 per Unit resulted in a total gross proceeds of $60,000,000.
Simultaneously with the closing
of the IPO, the Sponsor purchased an aggregate of 280,000 Private Placement Units at a price of $10.00 per unit for an aggregate purchase
price of $2,800,000. On November 19, 2024, simultaneously with the sale of the Over-Allotment Option Units, the Company consummated the
private sale of an additional 5,000 Private Placement Units, generating gross proceeds of $50,000. Each Private Placement Unit was identical
to the units sold in the IPO, except as described below.
There will be no redemption
rights or liquidating distributions from the Trust Account with respect to the Founder Shares, Private Placement Units, shares underlying
the Private Placement Units (“Private Placement Shares”) or the rights included in the Private Placement Units (“Private
Placement Rights”).
The Private Placement Units,
Private Placement Shares, Private Placement Rights and the Class A ordinary shares underlying such rights will not be transferable, assignable
or salable by the Sponsor until after the completion of the Company’s initial Business Combination, except to permitted transferees.
Following the IPO and the
sale of the Private Placement Units, including the sale of the Over-Allotment Option Units, a total of $60,000,000 was placed in the Trust
Account, and the Company had $1,888,753 of cash held outside of the Trust Account, after payment of costs related to the Initial Public
Offering, and available for working capital purposes. The Company incurred $1,600,217 in transaction costs, including $600,000 of underwriting
fees, the fair value of the representative shares of $675,000, and $325,217 of other offering costs. We intend to use substantially all
of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less income taxes payable),
to complete our Business Combination. To the extent that our share capital or debt is used, in whole or in part, as consideration to complete
our Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of
the target business or businesses, make other acquisitions and pursue our growth strategies. Such working capital funds could be used
in a variety of ways and could also be used to repay any operating expenses or finders’ fees which we had incurred prior to the
completion of our Business Combination or to indemnify any of our officers or directors as required by law if the funds available to us
outside of the Trust Account were insufficient to cover such expenses. On January 24, 2025, the Company repaid the Promissory Note in
full. As of December 31, 2025, no amount was outstanding under the promissory note with our Sponsor.
22
As of December 31, 2025, we
had marketable securities held in the Trust Account of $2,979,936 (including approximately $2,171,231 of interest income for the year
ended December 31, 2025) consisting of U.S. Treasury Bills with a maturity of 185 days or less. We may withdraw interest from the Trust
Account to pay taxes, if any.
As of December 31, 2025, the
Company had $871,350 of cash on hand and working capital of $419,761.
In order to fund working capital
deficiencies or finance transaction costs in connection with an intended initial business combination, our Sponsor or an affiliate of
our Sponsor or certain of our officers and directors may, but are not obligated to, loan us funds as may be required (the “Working
Capital Loan”). If we complete our initial business combination, we would repay such loaned amounts. In the event that our initial
business combination does not close, we may use a portion of the working capital held outside the trust account to repay such loaned amounts
but no proceeds from our trust account would be used for such repayment. Up to $1,150,000 of such loans may be convertible into units
at a price of $10.00 per unit at the option of the lender. The units would be identical to the Private Placement Units issued to our Sponsor.
The terms of such loans by our officers and directors, if any, have not been determined and no written agreements exist with respect to
such loans. We do not expect to seek loans from parties other than our Sponsor or an affiliate of our Sponsor as we do not believe third
parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account.
As of December 31, 2025 and 2024, no borrowing was outstanding under the Working Capital Loan.
The Company has incurred and
expects to continue to incur significant costs to remain as a publicly traded company and to incur significant transaction costs in pursuit
of the consummation of a Business Combination. We do not believe we will need to raise additional funds in order to meet the expenditures
required for operating our business. However, if our estimate of the costs of identifying a target business, undertaking in-depth due
diligence and negotiating a Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available
to operate our business prior to our initial Business Combination. Moreover, we may need to obtain additional financing either to complete
our Business Combination or because we become obligated to redeem a significant number of our public shares upon completion of our Business
Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance
with applicable securities laws, we would only complete such financing simultaneously with the completion of our Business Combination.
If we are unable to complete our Business Combination because we do not have sufficient funds available to us, we will be forced to cease
operations and liquidate the Trust Account. In addition, following our Business Combination, if cash on hand is insufficient, we may need
to obtain additional financing in order to meet our obligations.
In addition, if the Company
is unable to complete a business combination 24 months from the closing of the IPO, the Company’s board of directors would proceed
to commence a voluntary liquidation and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans
to consummate a Business Combination will be successful. In connection with the Company’s assessment of going concern considerations
in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15,
“Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that
these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The management’s plan
in addressing this uncertainty is through the Working Capital Loans (see Note 5). In addition, if the Company is unable to complete a
business combination within the Combination Period, the Company’s board of directors would proceed to commence a voluntary liquidation
and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans to consummate a Business Combination
will be successful within the Combination Period. As a result, management has determined that such an additional condition also raises
substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
Off-Balance Sheet Financing Arrangements
We have no obligations, assets
or liabilities, which would be considered off-balance sheet arrangements as of December 31, 2025. We do not participate in transactions
that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which
would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet
financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any
non- financial assets.
23
Contractual Obligations
We do not have any material
long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than described below.
Registration Rights
The holders of the Founder
Shares, Private Placement Units, shares being issued to the underwriters of the IPO, and private units that may be issued on conversion
of Working Capital Loans (and in each case holders of their component securities, as applicable) will be entitled to registration rights
pursuant to a registration rights agreement signed on the effective date of the IPO. The holders of these securities are entitled to make
up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back”
registration rights with respect to registration statements filed subsequent to the consummation of a Business Combination and rights
to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. Notwithstanding the foregoing,
the underwriter may not exercise its demand and “piggyback” registration rights after five (5) and seven (7) years, respectively,
after the effective date of the IPO and may not exercise its demand rights on more than one occasion. However, the registration rights
agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until
termination of the applicable Lock-up period, which occurs (i) in the case of the Founder Shares, on the earlier of (A) six months after
the completion of the initial business combination or (B) subsequent to the initial business combination, (x) if the last sale price of
Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for share splits, share capitalizations, rights issuances, subdivisions,
reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing after the initial
business combination, or (y) the date on which the Company completes a liquidation, merger, share exchange, reorganization or other similar
transaction after the completion of the initial business combination that results in all of the Company’s public shareholders having
the right to exchange their Class A ordinary shares for cash, securities or other property, and (ii) in the case of the private placement
units, including the component securities therein, until the completion of the initial business combination. Notwithstanding the above,
the shares to be issued to the underwriters in the IPO will be further subject to the limitations on registration requirements imposed
by FINRA Rule 5110(g)(8). The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriting Agreement
Pursuant to the underwriting agreement entered into on November 8,
2024, we issued to Maxim 247,500 Class A ordinary shares at the closing of the IPO (such Class A ordinary shares issued to the underwriter,
the “Representative Shares”). As a result of the underwriter’s partial exercise of the over-allotment option on November
15, 2024, an additional 22,500 Representative Shares were issued to the underwriter. Maxim has agreed not to transfer, assign or sell
any such Representative Shares until the completion of the initial Business Combination. In addition, the underwriter has agreed (and
its permitted transferees will agree) (i) to waive its redemption rights with respect to such Representative Shares in connection with
the completion of the Company’s initial Business Combination and (ii) to waive its rights to liquidating distributions from the
Trust Account with respect to such Representative Shares if the Company fails to complete its initial Business Combination within the
Combination Period.
The Representative Shares
have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the date
of the commencement of sales in the IPO pursuant to FINRA Rule 5110(e)(1). Pursuant to FINRA Rule 5110(e)(1), these securities will not
be the subject of any hedging, short sale, derivative, put or call transaction that would result in the economic disposition of the securities
by any person for a period of 180 days immediately following the effective date of the IPO, nor may they be sold, transferred, assigned,
pledged or hypothecated for a period of 180 days immediately following the effective date of the IPO except to any underwriter and selected
dealer participating in the IPO and their officers, partners, registered persons or affiliates.
24
Merger Agreement
On May 23, 2025, the Company
entered into the Merger Agreement with (i) Bioserica, (ii) PubCo, and (iii) Merger Sub.
Pursuant to the Merger
Agreement, among other things, (i) the Company will merge with and into PubCo, the separate corporate existence will cease and PubCo
will continue as the surviving corporation (the “Reincorporation Merger”), and (ii) the Merger Sub will merge with and
into Bioserica and Bioserica will continue as the surviving company under the laws of the British Virgin Islands and become a wholly
owned subsidiary of PubCo (the “Acquisition Merger”). Pursuant to the terms of the Merger Agreement, the aggregate
consideration for the Acquisition Merger is $217,860,000, consisting of (i) $200,000,000, payable in the form of 20,000,000 newly
issued PubCo Class B ordinary shares, valued at $10.00 per share; and (ii) $17,860,000, payable in the form of 1,786,000 newly
issued PubCo Class A ordinary shares, valued at $10.00 per share (assuming that Bioserica would receive an aggregate of $12,500,000
investment from third parties prior to Closing).
The Merger Agreement contains
customary representations, warranties and covenants of the parties thereto. The consummation of the proposed Merger is subject to certain
conditions as further described in the Merger Agreement.
Concurrently with the execution
of the Merger Agreement, Bioserica, PubCo, the Company and a shareholder of Bioserica (the “Supporting Shareholder”) entered
into a voting and support agreement (“Voting and Support Agreement”) pursuant to which such the Supporting Shareholder has
agreed, among other things, to vote in favor of the Acquisition Merger, the adoption of the Merger Agreement and any other matters necessary
or reasonably requested by Bioserica, PubCo or the Company for consummation of the Acquisition Merger and the other transactions contemplated
by the Merger Agreement. In addition, the Supporting Shareholder has agreed not to sell, assign, encumber, pledge, hypothecate, dispose,
loan or otherwise transfer the shares of the Company owned of record and beneficially by such Supporting Shareholder or over which such
Supporting Shareholder has voting power, prior to the earlier to occur of (a) the closing of the Acquisition Merger, (b) the termination
of the Merger Agreement, and (c) written agreement of the Supporting Shareholder, on the one hand, and the Company and PubCo, on the other
hand.
Critical Accounting Policies and Estimates
The preparation of financial
statements and related disclosures in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and income
and expenses during the periods reported. Actual results could materially differ from those estimates. We have not identified any critical
accounting estimates. We have identified the following critical accounting policies:
Class A Ordinary Shares Subject to Possible
Redemption
The Company accounts for Class
A ordinary shares subject to possible redemption in accordance with the guidance in ASC 480. Class A ordinary shares subject to mandatory
redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including
ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence
of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares
are classified as stockholders’ equity. The Class A ordinary shares feature certain redemption rights that are considered to be
outside of the Company’s control and subject to the occurrence of uncertain future events. In accordance with the SEC and its guidance
on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of a
company require ordinary shares subject to redemption to be classified outside of permanent equity. Given that the 6,000,000 Class A ordinary
shares sold as part of the Company’s IPO were issued with other freestanding instruments (i.e., Public Rights), the initial carrying
value of Class A ordinary shares classified as temporary equity has been allocated to the proceeds determined in accordance with ASC 470-20.
The Company’s Class A ordinary shares are subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable,
the Company has the option to either (i) accrete changes in the redemption value over the period from the date of issuance (or from the
date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument
or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal
the redemption value at the end of each reporting period. The Company has elected to recognize the changes in redemption value in additional
paid-in capital (or accumulated deficit in the absence of additional paid-in capital) over an expected 12-month period, which is the initial
period that the Company has to complete a Business Combination.
25
Subsequent to the IPO date,
the accretion also includes the dividend and interest income earned in the Trust Account in excess of income and franchise taxes, if any.
Net Income (Loss) per Share
The Company complies with
accounting and disclosure requirements of FASB ASC 260, Earnings Per Share. Net loss per share is computed by dividing net loss by the
weighted average number of ordinary shares outstanding during the period, excluding ordinary shares subject to forfeiture by the Sponsor.
Recent Accounting Standards
In November 2023, the FASB
issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires the disclosure of
additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within
fiscal years beginning after December 15, 2024. The Company adopted this guidance on January 1, 2025 and there was no significant impact.
In December 2023, the FASB
issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which requires disclosure of incremental
income tax information within the rate reconciliation and expanded disclosures of income taxes paid, among other disclosure requirements.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted. Our management is currently
evaluating this ASU to determine its impact on the Company’s disclosures.
Management does not believe
that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our financial
statements.
JOBS Act
On April 5, 2012, the JOBS
Act was signed into law. The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying
public companies. We will qualify as an “emerging growth company” and under the JOBS Act will be allowed to comply with new
or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay
the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the
relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, our financial statements
may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.
Additionally, we are in the
process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain
conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not
be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial
reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public
companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by
the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about
the audit and the financial statements (auditor discussion and analysis), and (iv) disclose certain executive compensation related items
such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee
compensation. These exemptions will apply for a period of five years following the completion of our initial public offering or until
we are no longer an “emerging growth company,” whichever is earlier.
26
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As smaller reporting company
we are not required to make disclosures under this Item.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
This information appears following
Item 15 of this Report and is included herein by reference.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.